These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 17703529

  • 1. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R, Camm J, McClung M.
    N Engl J Med; 2007 Aug 16; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract] [Full Text] [Related]

  • 2. Yearly zoledronic acid in postmenopausal osteoporosis.
    de Nijs RN, Westgeest AA.
    N Engl J Med; 2007 Aug 16; 357(7):711; author reply 714-5. PubMed ID: 17699824
    [No Abstract] [Full Text] [Related]

  • 3. Yearly zoledronic acid in postmenopausal osteoporosis.
    Poole KE, Kaptoge S, Reeve J.
    N Engl J Med; 2007 Aug 16; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
    [No Abstract] [Full Text] [Related]

  • 4. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG, Stavropoulos MF, Bowers LM, Neuman AN, Hinkson DW, Green JG, Bhattacharyya I, Cohen DM.
    J Oral Maxillofac Surg; 2012 Feb 16; 70(2):325-30. PubMed ID: 21723015
    [No Abstract] [Full Text] [Related]

  • 5. Alendronate and atrial fibrillation.
    Cummings SR, Schwartz AV, Black DM.
    N Engl J Med; 2007 May 03; 356(18):1895-6. PubMed ID: 17476024
    [No Abstract] [Full Text] [Related]

  • 6. Yearly zoledronic acid in postmenopausal osteoporosis.
    Chang JT.
    N Engl J Med; 2007 Aug 16; 357(7):713-4; author reply 714-5. PubMed ID: 17703528
    [No Abstract] [Full Text] [Related]

  • 7. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD.
    MMW Fortschr Med; 2009 Mar 05; 151(10):7. PubMed ID: 19472655
    [No Abstract] [Full Text] [Related]

  • 8. [Osteoporosis and bisphosphonates].
    Zuber MA.
    Z Rheumatol; 2007 Dec 05; 66(8):713-5. PubMed ID: 17955251
    [No Abstract] [Full Text] [Related]

  • 9. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May 03; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK, Tam KL, Krishnan SP, Maddern IL.
    N Z Med J; 2014 Feb 14; 127(1389):81-5. PubMed ID: 24548959
    [Abstract] [Full Text] [Related]

  • 12. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov 05; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract] [Full Text] [Related]

  • 13. Going on a drug holiday?
    Bonnick SL.
    J Clin Densitom; 2011 Nov 05; 14(4):377-83. PubMed ID: 22051091
    [No Abstract] [Full Text] [Related]

  • 14. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul 05; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 15. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
    Anastasilakis AD, Goulis DG, Kita M, Avramidis A.
    Hormones (Athens); 2007 Jul 05; 6(3):233-41. PubMed ID: 17724008
    [Abstract] [Full Text] [Related]

  • 16. [FACT study].
    Tanaka I, Oshima H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract] [Full Text] [Related]

  • 17. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb 28; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 18. Yearly zoledronic acid in postmenopausal osteoporosis.
    Najib MA, Aziz I.
    N Engl J Med; 2007 Aug 16; 357(7):713; author reply 714-5. PubMed ID: 17703527
    [No Abstract] [Full Text] [Related]

  • 19. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
    Hochberg MC.
    Curr Osteoporos Rep; 2008 Sep 16; 6(3):89-94. PubMed ID: 18752769
    [Abstract] [Full Text] [Related]

  • 20. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
    Geusens PP, Lems WF.
    Ned Tijdschr Geneeskd; 2007 Jun 30; 151(26):1445-8. PubMed ID: 17633971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.